What You Should Know
- The Funding: AcuityMD has secured an $80M Series C led by StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. The company has now raised over $160M and boasts a $955M valuation.
- The Market Traction: The platform is currently used by over 400 MedTech companies, including 16 of the top 20 global organizations. To date, AcuityMD has helped customers identify over $34 billion in pipeline.
- The Agentic AI Rollout: AcuityMD is using the fresh capital to accelerate AcuityAI (currently in open beta). This agentic AI leverages the underlying ontology to allow reps and sales leaders to query complex business questions and receive immediate, actionable business plans regarding territory prioritization and market trends.
- The Future Vision: Beyond commercial sales, AcuityMD plans to expand its platform across the full product lifecycle, aiding in the research, development, and launch phases of next-generation medical innovations.
Mapping the MedTech Landscape
MedTech companies operate in a high-pressure environment where hospital consolidation, regulatory changes, and reimbursement updates can rapidly shift the competitive landscape. AcuityMD addresses this by aggregating fragmented data—including claims databases, FDA filings, and government records—into a proprietary MedTech ontology.
This continuously enriched knowledge graph maps:
- Entities: Detailed profiles of physicians, facilities, and networks.
- Market Dynamics: Real-time tracking of procedures and reimbursement trends.
- Internal Alignment: Integrating a customer’s specific contracting info, product indications, and CRM activity into a unified view.
AcuityAI: Insights at the Point of Action
Currently in open beta, AcuityAI leverages this data foundation to surface specific commercial answers that general AI platforms cannot replicate. The tool is designed to help sales representatives spend less time on research and more time engaging the right physicians with the correct context.
“Insights that used to take hours are now surfaced right when our reps need them,” said Mark Edwards, senior director of sales operations at Kuros Biosciences. “One of our sales leaders asked AcuityAI for intel on a new national contract… and quickly had a full business plan: where to go, which surgeons to prioritize, and more.”
Expanding Beyond Commercial Execution
While AcuityMD is already trusted by over 400 companies and has helped identify more than $34 billion in pipeline, the new funding will support three primary growth pillars:
- Agentic AI: Developing specialized AI agents for sales, marketing, and leadership personas.
- Ontology Depth: Further deepening the data model that serves as the platform’s “context layer.”
- Full Lifecycle Support: Moving beyond commercial execution to support medical technology adoption from pre-commercial stages through the entire product lifecycle.
